Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its price objective dropped by equities research analysts at Morgan Stanley from $42.00 to $37.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential upside of 97.44% from the stock’s previous close.
DNLI has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Thursday, October 15th. Wedbush boosted their price target on Denali Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 4th. HC Wainwright started coverage on Denali Therapeutics in a research note on Wednesday, November 4th. They issued a “strong-buy” rating on the stock. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Finally, Deutsche Bank raised their price objective on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $35.71.
Check Out Our Latest Analysis on DNLI
Denali Therapeutics Stock Performance
DNLI stock traded down $0.15 during trading hours on Friday, reaching $18.74. The stock had a trading volume of 795,673 shares, compared to its average volume of 1,678,008. The stock has a 50-day simple moving average of $19.77 and a 200 day simple moving average of $21.25. Denali Therapeutics has a fifty-two week low of $15.34 and a fifty-two week high of $27.30. The stock has a market capitalization of $3.00 billion, a PE ratio of -10.83 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.21 and a quick ratio of 5.94.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.67 million. During the same quarter in the prior year, the firm earned ($0.74) earnings per share. Analysts predict that Denali Therapeutics will post -2.62 EPS for the current fiscal year.
Insider Activity
In related news, insider Alexander O. Schuth sold 2,768 shares of Denali Therapeutics stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the sale, the insider owned 278,995 shares of the company’s stock, valued at approximately $6,539,642.80. The trade was a 0.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.70% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of DNLI. Marshall Wace LLP grew its position in shares of Denali Therapeutics by 46.1% in the third quarter. Marshall Wace LLP now owns 803,420 shares of the company’s stock valued at $16,607,000 after purchasing an additional 253,590 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of Denali Therapeutics by 65.9% during the third quarter. Global Retirement Partners LLC now owns 1,830 shares of the company’s stock worth $38,000 after purchasing an additional 727 shares during the period. Aberdeen Group plc increased its stake in shares of Denali Therapeutics by 13.0% during the third quarter. Aberdeen Group plc now owns 1,520,605 shares of the company’s stock worth $31,431,000 after purchasing an additional 175,124 shares during the period. Fisher Asset Management LLC lifted its holdings in Denali Therapeutics by 1.9% during the 3rd quarter. Fisher Asset Management LLC now owns 2,460,545 shares of the company’s stock worth $50,859,000 after purchasing an additional 46,383 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Denali Therapeutics by 19.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 102,813 shares of the company’s stock worth $2,125,000 after purchasing an additional 16,781 shares during the last quarter. 92.92% of the stock is owned by institutional investors.
About Denali Therapeutics
Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California. Its research and development programs target conditions including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.
See Also
- Five stocks we like better than Denali Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
